How to Build a Biotech Watchlist from Company Names
Learn how to build a biotech watchlist from company names, focus on the right stocks, and keep your news coverage manageable.
What Is a Biosimilar and Why Does It Matter for Biotech Investors?
Learn what a biosimilar is, why it matters for biologic competition, and how biosimilar news can affect original drug markets.
What Is a First-in-Class Drug?
Learn what first-in-class means in biotech, why it matters for drug innovation, and how investors use the term to judge novelty and risk.
What Is a Phase 3 Data Release? Why It Usually Has the Biggest Impact
Learn what a Phase 3 data release is, why late-stage readouts matter most, and how investors use Phase 3 results to judge approval and launch potential.
What Is a Phase 1 Data Release? Why Early-Stage Readouts Matter
Learn what a Phase 1 data release is, what investors look for in early biotech data, and why first-in-human readouts can shape market sentiment.
What Is a Clinical Trial Readout? Why It Often Shapes Market Sentiment
Learn what a clinical trial readout is, what investors look for in biotech data releases, and why readouts often move stocks and market sentiment.
What Is an FDA Calendar? Why Investors and Industry Teams Watch It
Learn what an FDA calendar is, which FDA milestones it tracks, and why investors and biotech teams rely on it to follow upcoming catalysts.